Heart Failure / EHR-Emedded Alert · Interventional Study

Multi-Center Project: Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure

ClinicalTrials.gov · August 17, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a completed multi-center interventional study registration testing an EHR-embedded alert to improve prescribing of mineralocorticoid antagonists in heart failure with reduced ejection fraction. No results are posted in this registry record; the trial design and recruitment completion are documented but the clinical outcomes remain unreported.

What was studied

Interventional, Randomized, Parallel, Open label, Health Services Research purpose. Heart Failure; age from 18 Years; to 90 Years. Intervention: Intervention. Compared with: Standard of Care — No Intervention. n = 1,136. 4 sites: United States.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

Results from this multi-center implementation study will inform whether EHR-embedded alerts can improve guideline-directed prescribing of mineralocorticoid antagonists across diverse health systems. Clinical significance cannot be assessed until outcomes are reported.

Plain-language summary

This is a completed clinical trial registry record with no reported results; the study design and planned enrollment are documented but outcomes have not yet been published or posted.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Number of Patients with a Prescription for Mineralocorticoid Antagonists (MRA) (assessed at Up to Day 30)

DesignInterventional, Randomized, Parallel, Open label, Health Services Research purpose

PopulationHeart Failure; age from 18 Years; to 90 Years

Sample size1,136

InterventionIntervention

ComparatorStandard of Care — No Intervention

Setting4 sites: United States

Reported figures

Quoted from the source exactly as published.

Planned enrollment1136

Primary outcome measureNumber of Patients with a Prescription for Mineralocorticoid Antagonists (MRA), Up to Day 30

Study statusRecruitment COMPLETED

Clinical bottom line

Caveats

No outcome results are posted in this registry record.
No comparator arm or control condition is described; study may be single-arm.
Blinding status and analytical approach are not described in the registry record.
Follow-up duration beyond Day 30 and longer-term clinical outcomes are not specified.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Interventional design testing EHR-embedded alert; multi-center implementation study.

Directness

strong

Tests clinical intervention (alert) directly on prescribing of guideline-directed therapy.

Consistency

insufficient

No results reported; consistency with other evidence cannot be assessed.

Risk of bias

insufficient

Registry record does not describe blinding, comparator arm, or analytical approach.

Sample adequacy

strong

Planned enrollment 1136 participants across four health systems including lead site.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT06457152). This is a study registration, not published results. Lead sponsor: NYU Langone Health. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 1136 participants (ACTUAL). Conditions: Heart Failure. Interventions: OTHER: EHR-Emedded Alert. Primary outcome measures: Number of Patients with a Prescription for Mineralocorticoid Antagonists (MRA) , Up to Day 30. Brief summary: This study will test an automated, electronic health record (EHR-)embedded alert to improve prescribing of guideline-directed medical therapy for patients with heart failure and reduced ejection fraction (HFrEF). The investigators have previously tested and implemented this alert at NYU Langone Health (NYULH), and will now test and implement this alert across three other health systems.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Heart FailureNCT06457152EHR-Emedded AlertNYU Langone Health